Leerink Partnrs Issues Optimistic Forecast for BNTC Earnings

Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) - Equities research analysts at Leerink Partnrs increased their FY2025 earnings per share (EPS) estimates for Benitec Biopharma in a research note issued on Wednesday, May 14th. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnology company will post earnings of ($1.18) per share for the year, up from their previous estimate of ($1.22). The consensus estimate for Benitec Biopharma's current full-year earnings is ($1.48) per share. Leerink Partnrs also issued estimates for Benitec Biopharma's Q4 2025 earnings at ($0.26) EPS and FY2026 earnings at ($1.05) EPS.

A number of other brokerages have also commented on BNTC. HC Wainwright reiterated a "buy" rating and set a $28.00 price target on shares of Benitec Biopharma in a report on Monday, May 19th. JMP Securities reaffirmed a "market outperform" rating and set a $20.00 price target on shares of Benitec Biopharma in a research report on Thursday, May 15th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $24.71.

Benitec Biopharma Stock Performance

Shares of BNTC traded down $0.40 during mid-day trading on Monday, reaching $13.19. 36,388 shares of the company were exchanged, compared to its average volume of 41,273. Benitec Biopharma has a 52 week low of $5.74 and a 52 week high of $16.90. The stock has a market capitalization of $337.66 million, a PE ratio of -8.74 and a beta of 0.34. The business has a 50 day simple moving average of $13.54 and a two-hundred day simple moving average of $12.13.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.12.

Insider Transactions at Benitec Biopharma

In related news, Director Suvretta Capital Management, L purchased 900,000 shares of the company's stock in a transaction that occurred on Wednesday, March 26th. The stock was purchased at an average price of $13.00 per share, with a total value of $11,700,000.00. Following the completion of the transaction, the director now owns 8,793,245 shares of the company's stock, valued at approximately $114,312,185. This trade represents a 11.40% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.30% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Franklin Resources Inc. raised its position in shares of Benitec Biopharma by 269.0% during the 4th quarter. Franklin Resources Inc. now owns 2,939,287 shares of the biotechnology company's stock worth $37,123,000 after buying an additional 2,142,643 shares in the last quarter. Janus Henderson Group PLC raised its stake in Benitec Biopharma by 198.5% during the 4th quarter. Janus Henderson Group PLC now owns 2,616,427 shares of the biotechnology company's stock valued at $33,268,000 after purchasing an additional 1,739,904 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its stake in shares of Benitec Biopharma by 134.4% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,972,524 shares of the biotechnology company's stock valued at $24,913,000 after buying an additional 1,131,129 shares in the last quarter. Infinitum Asset Management LLC increased its position in shares of Benitec Biopharma by 435.7% during the 1st quarter. Infinitum Asset Management LLC now owns 1,125,000 shares of the biotechnology company's stock worth $14,636,000 after purchasing an additional 915,000 shares in the last quarter. Finally, Suvretta Capital Management LLC increased its position in shares of Benitec Biopharma by 1.5% during the 4th quarter. Suvretta Capital Management LLC now owns 8,960,009 shares of the biotechnology company's stock worth $113,165,000 after purchasing an additional 130,956 shares in the last quarter. 52.19% of the stock is currently owned by institutional investors.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.